Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Melanoma 13Carcinoma, Hepatocellular 13Neoplasm Metastasis 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Esophageal Neoplasms 9Colorectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Recurrence 4Rectal Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Liver Neoplasms 3Head and Neck Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Immunotherapy × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡